Modified ubiquitin proteins having a specific binding activity for the extradomain b of fibronectin

The present invention refers to novel hetero-multimeric proteins obtained from modified ubiquitin capable of binding the extradomain B of fibronectin (ED-B) with high affinity. Furthermore, the invention refers to fusion proteins comprising said recombinant protein fused to a pharmaceutically and/or...

Full description

Saved in:
Bibliographic Details
Main Authors ARND STEUERNAGEL, THOMAS GOETTLER, ERIK FIEDLER, MANJA GLOSER, MARKUS FIEDLER, ILKA HAENSSGEN, ANJA KUNERT, JOERG NERKAMP
Format Patent
LanguageEnglish
Hebrew
Published 28.09.2017
Subjects
BEER
BIOCHEMISTRY
CHEMISTRY
COMBINATORIAL CHEMISTRY
COMPOSITIONS THEREOF
CULTURE MEDIA
ENZYMOLOGY
INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIRCHEMICAL OR PHYSICAL PROPERTIES
LIBRARIES, e.g. CHEMICAL LIBRARIES, IN SILICOLIBRARIES
MEASURING
METALLURGY
MICROBIOLOGY
MICROORGANISMS OR ENZYMES
MUTATION OR GENETIC ENGINEERING
ORGANIC CHEMISTRY
PEPTIDES
PHYSICS
PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS
SPIRITS
TESTING
VINEGAR
WINE
Online AccessGet full text

Cover

More Information
Summary:The present invention refers to novel hetero-multimeric proteins obtained from modified ubiquitin capable of binding the extradomain B of fibronectin (ED-B) with high affinity. Furthermore, the invention refers to fusion proteins comprising said recombinant protein fused to a pharmaceutically and/or diagnostically active component. The invention is further directed to the use of said proteins in medical treatment methods.
Bibliography:Application Number: IL20120219755